Retinoid x receptor modulators

a technology of retinoids and receptors, applied in the field of retinoids with receptor modulators, can solve the problems of many undesirable side effects of retinoids, skin irritation, lipid and bone toxicity, etc., and achieve the effect of fewer side effects

Inactive Publication Date: 2008-04-17
GARDINIER KEVIN +6
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] RXR modulators bind to RXR homo- or heterodimers and either increase or decrease their ability to activate transcription of genes that control cellular differentiation and proliferation. Conditions mediated by retinoid X receptors include diabetes, dermatologic diseases, inflammatory diseases, neurodegenerative diseases, obesity, cardiovascular diseases, cancer and other proliferative diseases, such as atherosclerosis, uterine leiomyomata. In addition, RXR modulators can be used to promote wound healing or to stimulate hair growth.

Problems solved by technology

RXR modulators which have been identified so far have exhibited significant therapeutic utility, but they have also exhibited some undesirable side effects.
In addition, many retinoids have undesirable side effects such as skin irritation, lipid and bone toxicity, visual effects (including night blindness and dry eye) and teratogenicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Retinoid x receptor modulators
  • Retinoid x receptor modulators
  • Retinoid x receptor modulators

Examples

Experimental program
Comparison scheme
Effect test

example 1

3-[5-(2-Hydroxy-3-tert-butyl-5-ethylphenyl)-benzo[b]furan-2-yl]-but-2-enoic acid

[0292]

A. 2-Hydroxy-5-(5-ethyl-3-tert-butyl-2-methoxymethoxyphenyl)-benzaldehyde

[0293]

[0294] To a mixture of 91 mg (0.078 mmol, 5%) of Pd(PPh3)4 and 252 mg (1.26 mmol) of 5-bromo salicylaldehyde in 10 mL of dry toluene was added 685 mmol (2.5 mmol, 2 equivalents) of 2-methoxymethoxy-3-tert-butyl-5-ethyl phenylboronic acid diluted in 5 mL of ethanol followed by 1.3 mL of a 2N aqueous solution of Na2CO3. The mixture was stirred at reflux for 3 hours and after cooling extracted with ethyl acetate. The organic layer was dried over MgSO4 and evaporated under reduced pressure. The residual oil was purified over silica gel (eluent: ethyl acetate / hexane:10 / 90) to give 333 mg (0.969 mmol, yield: 77%) of 2-hydroxy-5-(5-ethyl-3-tert-butyl-2-methoxymethoxyphenyl)-benzaldehyde a pale brown oil. 1H NMR (CDCl3), δ: 11.04 (s, 1H), 9.95 (s, 1H), 7.75 (dd, J=8.9, 2.1 Hz, 1H), 7.74 (d, J=2.1 Hz, 1H), 7.19 (d, J=2.1 Hz, 1H...

example 2

2-Fluoro-3-[5-(2-methoxy-3,5-diisopropylphenyl)-benzo[b]furan-2-yl]-but-2-enoic acid

[0302]

A. 2-Acetyl-5-bromo benzo[b]furan

[0303]

[0304] A mixture of 5.0 g (24.9 mmol) of 5-bromo-salicylaldehyde, 3.0 g (32.3 mmol, 2.6 mL) of chloroacetone and 12 g (37.2 mmol) of Cs2CO3 in 30 mL of dry DMF was heated to 60° C. overnight. After cooling at room temperature, water (100 mL) was added and the mixture was extracted with ethyl acetate. The organic layer was dried over MgSO4 and the solvents were removed under reduced pressure. The crude product was directly recrystallized from hexane to afford 4.14 g (17.3 mmol, yield: 70%) of 2-acetyl-5-bromo benzo[b]furan as a pale orange crystal. 1H NMR (CDCl3), δ: 7.84 (d, J=1.9 Hz, 1H), 7.56 (dd, J=9.0, 2.1 Hz, 1H), 7.45 (d, J=8.9 Hz, 1H), 7.42 (s, 1H), 2.60 (s, 3H).

B. 2-Acetyl-5-[(2-methoxy-3,5-diisopropyl)-phenyl]benzo[b]furan

[0305]

[0306] To a mixture of 57 mg (0.049 mmol, 5%) of Pd(PPh3)4, 362 mg (1.26 mmol) of 2-acetyl-5-bromobenzo[b]furan and 2...

example 3

2-Fluoro-3-[7-(2-propoxy-3-tert-butyl-5-ethylphenyl)-benzo[b]furan-2-yl]-but-2-enoic acid ethyl ester

[0310]

A. 2-Acetyl-7-bromo benzo[b]furan

[0311]

[0312] A mixture of 5.0 g (24.9 mmol) of 3-bromo-salicylaldehyde, 3.0 g (32.3 mmol, 2.6 mL) of chloroacetone and 12 g (37.2 mmol) of Cs2CO3 in 30 mL of dry DMF was heated to 60° C. overnight. After cooling at room temperature, water (100 mL) was added and the mixture was extracted with ethyl acetate. The organic layer was dried over MgSO4 and the solvents were removed under reduced pressure. The crude product was directly recrystallized from hexane to afford 2-acetyl-7-bromo benzo[b]furan as a pale orange crystal.

B. 2-Acetyl-7-(2-propoxy-3-tert-butyl-5-ethylphenyl)benzo[b]furan

[0313]

[0314] To a mixture of 57 mg (0.049 mmol, 5%) of Pd(PPh3)4, 362 mg (1.26 mmol) of 2-acetyl-7-bromobenzo[b]furan and 2.52 mmol of 2-propoxy-3-tert-butyl-5-ethyl phenylboronic acid in 10 mL of toluene, and 5 mL of ethanol was added 1.3 mL of a 2N Na2CO3 aqueo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
weight percentaaaaaaaaaa
temperatureaaaaaaaaaa
Login to view more

Abstract

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof.

Description

RELATED APPLICATION(S) [0001] This application is a continuation of U.S. application Ser. No. 10 / 471,330, having a 371(c) filing date of Jan. 16, 2004, which is a U.S. National Stage of International Application No. PCT / US02 / 08292, filed on Mar. 14, 2002, published in English, which claims the benefit of U.S. Provisional Application No. 60 / 275,885, filed on Mar. 14, 2001. The entire teachings of the above application(s) are incorporated herein by reference.BACKGROUND OF THE INVENTION [0002] The vitamin A metabolite, retinoic acid, has long been recognized to induce a broad spectrum of biological effects. For example, retinoic acid-containing products, such as Retin-A® and Accutane®, have found utility as therapeutic agents for the treatment of various pathological conditions. In addition, a variety of structural analogues of retinoic acid have been synthesized that also have been found to be bioactive. Many of these synthetic retinoids have been found to mimic many of the pharmacolo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/437A61K31/343A61K31/381A61K31/405A61P17/00A61P3/06A61P35/00C07D209/18C07D231/56C07D471/04C07D333/64C07D333/52C07D307/82C07D261/20C07D217/04A61P9/00A61P3/10A61P25/28A61K31/472A61K31/416A61K31/423A61K31/426A61K31/4365A61K31/47A61K38/17A61K45/00A61P3/04A61P5/40A61P9/10A61P13/08A61P13/10A61P17/02A61P17/06A61P17/14A61P25/00A61P25/16A61P29/00A61P31/04A61P35/02A61P37/08A61P43/00C07D209/12C07D215/14C07D217/16C07D307/80C07D307/85C07D333/56C07D333/60C07D333/70C07D495/04
CPCC07D209/12C07D215/14C07D217/16C07D231/56C07D261/20C07D495/04C07D307/85C07D333/56C07D333/60C07D333/70C07D471/04C07D307/80A61P13/08A61P13/10A61P17/00A61P17/02A61P17/06A61P17/14A61P25/00A61P25/16A61P25/28A61P29/00A61P3/04A61P31/04A61P35/00A61P35/02A61P3/06A61P37/08A61P43/00A61P5/40A61P9/00A61P9/10A61P3/10
Inventor GARDINIER, KEVINGERNERT, DOUGLASGRESE, TIMOTHYNEEL, DAVIDMAPES, CHRISTOPHERMICHELLYS, PIERRE-YVESBOEHM, MARCUS
Owner GARDINIER KEVIN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap